Adolore Biotherapeutics has filed a notice of an exempt offering of securities to raise $1,055,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Adolore Biotherapeutics is raising up to $1,055,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Roelof Rongen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Adolore Biotherapeutics
Adolore Biotherapeutics, Inc. is a biotechnology company focused on developing best-in-class, long acting local anesthetics that are opioid-free Disease Modifying Anti-Pain therapies (DMAPs). The Company has two gene therapy product candidates currently in preclinical development for patients suffering from Erythromelalgia, an unmet medical need, and osteoarthritis knee pain, which is often treated with opioids contributing to the opioid crisis.
To learn more about Adolore Biotherapeutics, visit http://adolore.com/
Contact:
Roelof Rongen, Chief Executive Officer
215-622-4542
https://www.linkedin.com/in/roelof-rongen-6a11492/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.